Ameriprise
RYTM icon

Ameriprise’s Rhythm Pharmaceuticals RYTM Stock Holding History

Ameriprise’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.4M Buy
383,957
+122,797
+47% +$11.9M 0.01% 1087
2025
Q4 		$28M Buy
261,160
+123,193
+89% +$13.1M 0.01% 1183
2025
Q3 		$13.9M Sell
137,967
-35,102
-20% -$3.26M ﹤0.01% 1659
2025
Q2 		$10.9M Buy
173,069
+74,788
+76% +$4.58M ﹤0.01% 1750
2025
Q1 		$5.21M Buy
98,281
+44,914
+84% +$2.49M ﹤0.01% 2284
2024
Q4 		$2.99M Buy
53,367
+11,480
+27% +$634K ﹤0.01% 2696
2024
Q3 		$2.19M Buy
41,887
+1,472
+4% +$70.5K ﹤0.01% 2871
2024
Q2 		$1.66M Buy
40,415
+19,435
+93% +$776K ﹤0.01% 2946
2024
Q1 		$909K Hold
20,980
– – ﹤0.01% 3204
2023
Q4 		$964K Sell
20,980
-1,000
-5% -$31.5K ﹤0.01% 3202
2023
Q3 		$504K Buy
21,980
+3,840
+21% +$86K ﹤0.01% 3414
2023
Q2 		$299K Hold
18,140
– – ﹤0.01% 3607
2023
Q1 		$324K Hold
18,140
– – ﹤0.01% 3590
2022
Q4 		$528K Hold
18,140
– – ﹤0.01% 3388
2022
Q3 		$445K Hold
18,140
– – ﹤0.01% 3440
2022
Q2 		$75K Buy
+18,140
New +$99.3K ﹤0.01% 3810
2021
Q1 		– Sell
-8,410
Closed -$250K – 3892
2020
Q4 		$250K Buy
+8,410
New +$214K ﹤0.01% 3572
2020
Q1 		– Sell
-12,610
Closed -$290K – 3724
2019
Q4 		$290K Sell
12,610
-25,000
-66% -$555K ﹤0.01% 3486
2019
Q3 		$812K Buy
+37,610
New +$807K ﹤0.01% 3103

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Ameriprise's RYTM Position: Q1 2026 in Review

Ameriprise increased its Rhythm Pharmaceuticals (RYTM) stake by 47% in Q1 2026, buying an estimated $11.9M and bringing the position to 383,957 shares worth $33.4M. The position accounts for 0.01% of the portfolio, ranked #1087.

Ameriprise first reported a position in RYTM in Q3 2019 and has held it in 19 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Ameriprise held 383,957 shares of Rhythm Pharmaceuticals worth $33.4M as of Q1 2026.
  • Ameriprise bought 122,797 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $11.9M.
  • Rhythm Pharmaceuticals made up 0.01% of Ameriprise's portfolio in Q1 2026, its #1087 holding.
  • Ameriprise first reported a position in Rhythm Pharmaceuticals in Q3 2019 and has held it in 19 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.